Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2

Background: Angiotensin converting enzyme (ACE) 2 is a recently identified homologue of ACE that may counterregulate the actions of angiotensin (Ang) II by facilitating its breakdown to Ang 1–7. The renin-angiotensin system (RAS) has been implicated in the pathogenesis of cirrhosis but the role of ACE2 in liver disease is not known. Aims: This study examined the effects of liver injury on ACE2 expression and activity in experimental hepatic fibrosis and human cirrhosis, and the effects of Ang 1–7 on vascular tone in cirrhotic rat aorta. Methods: In sham operated and bile duct ligated (BDL) rats, quantitative reverse transcriptase-polymerase chain reaction was used to assess hepatic ACE2 mRNA, and western blotting and immunohistochemistry to quantify and localise ACE2 protein. ACE2 activity was quantified by quenched fluorescent substrate assay. Similar studies were performed in normal human liver and in hepatitis C cirrhosis. Results: ACE2 mRNA was detectable at low levels in rat liver and increased following BDL (363-fold; p<0.01). ACE2 protein increased after BDL (23.5-fold; p<0.05) as did ACE2 activity (fourfold; p<0.05). In human cirrhotic liver, gene (>30-fold), protein expression (97-fold), and activity of ACE2 (2.4 fold) were increased compared with controls (all p<0.01). In healthy livers, ACE2 was confined to endothelial cells, occasional bile ducts, and perivenular hepatocytes but in both BDL and human cirrhosis there was widespread parenchymal expression of ACE2 protein. Exposure of cultured human hepatocytes to hypoxia led to increased ACE2 expression. In preconstricted rat aorta, Ang 1–7 alone did not affect vascular tone but it significantly enhanced acetylcholine mediated vasodilatation in cirrhotic vessels. Conclusions: ACE2 expression is significantly increased in liver injury in both humans and rat, possibly in response to increasing hepatocellular hypoxia, and may modulate RAS activity in cirrhosis.

[1]  P. Macdonald,et al.  Myocardial infarction increases ACE2 expression in rat and humans. , 2005, European heart journal.

[2]  C. Johnston,et al.  ACE2, a new regulator of the renin–angiotensin system , 2004, Trends in Endocrinology & Metabolism.

[3]  Ching-lung Lai,et al.  SARS‐associated viral hepatitis caused by a novel coronavirus: Report of three cases , 2004, Hepatology.

[4]  D. Dimitrov.  The Secret Life of ACE2 as a Receptor for the SARS Virus , 2003, Cell.

[5]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[6]  M. Black,et al.  High Methionine and Cholesterol Diet Abolishes Endothelial Relaxation , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[7]  R. Bataller,et al.  Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. , 2003, Gastroenterology.

[8]  C. Yagil,et al.  Hypothesis: ACE2 modulates blood pressure in the mammalian organism. , 2003, Hypertension.

[9]  C. Johnston,et al.  Characterization of Renal Angiotensin-Converting Enzyme 2 in Diabetic Nephropathy , 2003, Hypertension.

[10]  K. Clark,et al.  Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme , 2002, FEBS letters.

[11]  P. Angus,et al.  Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. , 2002, Gastroenterology.

[12]  James M. Gavin,et al.  Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. , 2002, Journal of the American Chemical Society.

[13]  M. Crackower,et al.  Angiotensin-converting enzyme 2 is an essential regulator of heart function , 2002, Nature.

[14]  D. Wendum,et al.  Hypoxia‐induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis , 2002, Hepatology.

[15]  T. Parsons,et al.  Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase* , 2002, The Journal of Biological Chemistry.

[16]  P. Angus,et al.  Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. , 2001, Journal of hepatology.

[17]  Y Ando,et al.  Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. , 2001, Gastroenterology.

[18]  Nigel M. Hooper,et al.  A Human Homolog of Angiotensin-converting Enzyme , 2000, The Journal of Biological Chemistry.

[19]  K. Robison,et al.  A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9 , 2000, Circulation research.

[20]  D. Webb,et al.  Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. , 2000, Gastroenterology.

[21]  R. Henning,et al.  Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. , 1999, Hypertension.

[22]  D. Webb,et al.  Peripheral vascular tone in patients with cirrhosis: role of the renin-angiotensin and sympathetic nervous systems. , 1998, Cardiovascular research.

[23]  D. Diz,et al.  Counterregulatory actions of angiotensin-(1-7). , 1997, Hypertension.

[24]  C. Ferrario,et al.  Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. , 1996, Hypertension.

[25]  R. Busse,et al.  Release of nitric oxide by angiotensin‐(1–7) from porcine coronary endothelium: implications for a novel angiotensin receptor , 1994, British journal of pharmacology.

[26]  C. Johnston.  Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. , 1994, Hypertension.

[27]  J. Kountouras,et al.  Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. , 1984, British journal of experimental pathology.

[28]  K. Malik,et al.  Signal transduction mechanisms involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells. , 1998, The Journal of pharmacology and experimental therapeutics.